{
  "guideline": {
    "id": "PA166104989",
    "name": "Annotation of DPWG Guideline for atomoxetine and CYP2D6",
    "objCls": "Guideline Annotation",
    "source": "DPWG",
    "version": 33,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104989",
    "relatedChemicals": [
      {
        "id": "PA134688071",
        "name": "atomoxetine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166302044",
      "name": "Recommendation Annotation PA166302044",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103583,
        "html": "<ul>\n<li>Be extra alert to reduced efficacy of the treatment.</li>\n<li>Advise the patient to report an inadequate effect.</li>\n<li>An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.</li>\n</ul>\n"
      },
      "implications": [
        "Efficacy can be reduced due to the gene variation. The gene variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As a result, the plasma concentration of the active ingredients decreases."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302022",
      "name": "Recommendation Annotation PA166302022",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103561,
        "html": "<p>In the event of side effects occurring and/or a response later than 9 weeks: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 2-3 times higher for IM than for EM at the same dose.</p>\n"
      },
      "implications": [
        "The dose requirement can be reduced, because the genetic variation results in a higher atomoxetine plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "0.25"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302026",
      "name": "Recommendation Annotation PA166302026",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103565,
        "html": "<p>The guideline does not provide a recommendation for atomoxetine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on atomoxetine."
      ],
      "lookupKey": {
        "CYP2D6": "1.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302101",
      "name": "Recommendation Annotation PA166302101",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103640,
        "html": "<ul>\n<li>Be extra alert to reduced efficacy of the treatment.</li>\n<li>Advise the patient to report an inadequate effect.</li>\n<li>An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.</li>\n</ul>\n"
      },
      "implications": [
        "Efficacy can be reduced due to the gene variation. The gene variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As a result, the plasma concentration of the active ingredients decreases."
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302061",
      "name": "Recommendation Annotation PA166302061",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103600,
        "html": "<ul>\n<li>Be extra alert to reduced efficacy of the treatment.</li>\n<li>Advise the patient to report an inadequate effect.</li>\n<li>An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.</li>\n</ul>\n"
      },
      "implications": [
        "Efficacy can be reduced due to the gene variation. The gene variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As a result, the plasma concentration of the active ingredients decreases."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302043",
      "name": "Recommendation Annotation PA166302043",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103582,
        "html": "<ul>\n<li>Be extra alert to reduced efficacy of the treatment.</li>\n<li>Advise the patient to report an inadequate effect.</li>\n<li>An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.</li>\n</ul>\n"
      },
      "implications": [
        "Efficacy can be reduced due to the gene variation. The gene variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As a result, the plasma concentration of the active ingredients decreases."
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302030",
      "name": "Recommendation Annotation PA166302030",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103569,
        "html": "<ul>\n<li>Be extra alert to reduced efficacy of the treatment.</li>\n<li>Advise the patient to report an inadequate effect.</li>\n<li>An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.</li>\n</ul>\n"
      },
      "implications": [
        "Efficacy can be reduced due to the gene variation. The gene variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As a result, the plasma concentration of the active ingredients decreases."
      ],
      "lookupKey": {
        "CYP2D6": "3.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302021",
      "name": "Recommendation Annotation PA166302021",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103560,
        "html": "<ul>\n<li>Start with the normal initial dose, bearing in mind that an increase in this dose probably will not be required.</li>\n<li>Advise the patient to report side effects (such as decreased appetite, vomiting, abdominal pain, constipation, insomnia, early waking, drowsiness, irritability, pupil dilation and itching).</li>\n<li>If the medicine is effective, but side effects occur: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 8-11 times higher for PM than for NM at the same dose.</li>\n</ul>\n"
      },
      "implications": [
        "The risk of side effects is increased, because the genetic variation results in a higher atomoxetine plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "0.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302025",
      "name": "Recommendation Annotation PA166302025",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103564,
        "html": "<p>In the event of side effects occurring and/or a response later than 9 weeks: reduce the dose and check whether the effect is conserved The plasma concentration of atomoxetine is a factor of 2-3 times higher for IM than for NM at the same dose.</p>\n"
      },
      "implications": [
        "The dose requirement can be reduced, because the genetic variation results in a higher atomoxetine plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "1.0"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302029",
      "name": "Recommendation Annotation PA166302029",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103568,
        "html": "<p>The guideline does not provide a recommendation for atomoxetine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on atomoxetine."
      ],
      "lookupKey": {
        "CYP2D6": "2.25"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302042",
      "name": "Recommendation Annotation PA166302042",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103581,
        "html": "<ul>\n<li>Be extra alert to reduced efficacy of the treatment.</li>\n<li>Advise the patient to report an inadequate effect.</li>\n<li>An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.</li>\n</ul>\n"
      },
      "implications": [
        "Efficacy can be reduced due to the gene variation. The gene variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As a result, the plasma concentration of the active ingredients decreases."
      ],
      "lookupKey": {
        "CYP2D6": "4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302024",
      "name": "Recommendation Annotation PA166302024",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103563,
        "html": "<p>In the event of side effects occurring and/or a response later than 9 weeks: reduce the dose and check whether the effect is conserved The plasma concentration of atomoxetine is a factor of 2-3 times higher for IM than for NM at the same dose.</p>\n"
      },
      "implications": [
        "The dose requirement can be reduced, because the genetic variation results in a higher atomoxetine plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "0.75"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302081",
      "name": "Recommendation Annotation PA166302081",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103620,
        "html": "<ul>\n<li>Be extra alert to reduced efficacy of the treatment.</li>\n<li>Advise the patient to report an inadequate effect.</li>\n<li>An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.</li>\n</ul>\n"
      },
      "implications": [
        "Efficacy can be reduced due to the gene variation. The gene variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As a result, the plasma concentration of the active ingredients decreases."
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166302028",
      "name": "Recommendation Annotation PA166302028",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103567,
        "html": "<p>The guideline does not provide a recommendation for atomoxetine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on atomoxetine."
      ],
      "lookupKey": {
        "CYP2D6": "2.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302041",
      "name": "Recommendation Annotation PA166302041",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103580,
        "html": "<p>The guideline does not provide a recommendation for atomoxetine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on atomoxetine."
      ],
      "lookupKey": {
        "CYP2D6": "2.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302023",
      "name": "Recommendation Annotation PA166302023",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103562,
        "html": "<p>In the event of side effects occurring and/or a response later than 9 weeks: reduce the dose and check whether the effect is conserved. The plasma concentration of atomoxetine is a factor of 2-3 times higher for IM than for EM at the same dose.</p>\n"
      },
      "implications": [
        "The dose requirement can be reduced, because the genetic variation results in a higher atomoxetine plasma concentration."
      ],
      "lookupKey": {
        "CYP2D6": "0.5"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302027",
      "name": "Recommendation Annotation PA166302027",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103566,
        "html": "<p>The guideline does not provide a recommendation for atomoxetine in normal metabolizers.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a normal metabolizer phenotype on atomoxetine."
      ],
      "lookupKey": {
        "CYP2D6": "1.5"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166302102",
      "name": "Recommendation Annotation PA166302102",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA134688071",
          "name": "atomoxetine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452103641,
        "html": "<ul>\n<li>Be extra alert to reduced efficacy of the treatment.</li>\n<li>Advise the patient to report an inadequate effect.</li>\n<li>An alternative can be selected as a precaution. Clonidine is not metabolised by CYP2D6.</li>\n</ul>\n"
      },
      "implications": [
        "Efficacy can be reduced due to the gene variation. The gene variation results in an increased conversion of atomoxetine to the active metabolite 4-hydroxyatomoxetine, which has a much lower plasma concentration. As a result, the plasma concentration of the active ingredients decreases."
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": "36509836",
      "title": "Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate.",
      "authors": [
        "Nijenhuis Marga",
        "Soree Bianca",
        "Jama Wafa O M",
        "de Boer-Veger Nienke J",
        "Buunk Anne Marie",
        "Guchelaar Henk-Jan",
        "Houwink Elisa J F",
        "Rongen Gerard A",
        "van Schaik Ron H N",
        "Swen Jesse J",
        "Touw Daan",
        "van der Weide Jan",
        "van Westrhenen Roos",
        "Deneer Vera H M",
        "Risselada Arne"
      ],
      "journal": "European journal of human genetics : EJHG",
      "year": 2023,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689464"
    },
    {
      "pmid": "21412232",
      "title": "Pharmacogenetics: from bench to byte--an update of guidelines.",
      "authors": [
        "Swen J J",
        "Nijenhuis M",
        "de Boer A",
        "Grandia L",
        "Maitland-van der Zee A H",
        "Mulder H",
        "Rongen G A P J M",
        "van Schaik R H N",
        "Schalekamp T",
        "Touw D J",
        "van der Weide J",
        "Wilffert B",
        "Deneer V H M",
        "Guchelaar H-J"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2011,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pubmed/21412232"
    }
  ],
  "version": "2024-03-08-14-34"
}